Section 50-12-104 - Patient requirementsA patient is eligible for treatment with an investigational drug, biological product, or device if the patient has:
(1) considered all other treatment options currently approved by the United States food and drug administration;(2) received a recommendation from the patient's treating health care provider for an investigational drug, biological product, or device;(3) given written informed consent for the use of the investigational drug, biological product, or device; and(4) documentation from the treating health care provider that the patient meets the requirements of this section.Amended by Laws 2023, Ch. 413,Sec. 3, eff. 10/1/2023.Added by Laws 2015, Ch. 135, Sec. 4, eff. 3/27/2015.